Stem Cell Research News ($)
Stem Cell Business News ($)
The Stem Cell Trekker
Subscription Page
It's  

 

 

13th Edition Guide to Stem Cell Research Companies

Complete listing of global companies performing stem cell research... PLUS stem cell research suppliers AND for-profit cord blood banks! 214 companies in all ... Soon  available in a paperback edition.

Click for more information
Stem Cell Primer

27 pages ... PDF ... Everything you need to know about stem cells and stem cell science.

Only $5.00 (limited time offer)

Click here to order ...

How can I access archived ($) content? 

Start a subscription to Stem Cell Research News at the low individual annual rate to access ALL archived content on this Web site. All articles are posted for free access for seven days. Afterward, articles are archived and require a subscription. 

Click for more information

 
Scientists Produce CNS Cells From Neural Stem Cells - ($)
Friday, May 13, 2011 - Stem Cell Research News
Oligodendrocytes.png
 Oligodendrocytes (green) that formed myelin (red). Image courtesy MPI.
 

Researchers in Germany and France working in mice have succeeded in producing central nervous system cells from neural stem cells of the peripheral nervous system.

They found that if peripheral stem cells are maintained under defined growth conditions, they generate oligodendrocytes, which form the myelin layer that surrounds the neurons found in the brain and spinal cord. 

The mammalian nervous system consists of a central (brain, spinal cord) and peripheral nervous system (i.e., nerves and sensory ganglia). Although the two systems are very closely interlinked, they differ anatomically and consist of different cell types.

The cell types of the peripheral nervous system originate from precursor cells in the embryo called the neural crest. To date, it was believed that these neural crest stem cells could generate the neurons and support cells, known as glial cells, of the peripheral nervous system, but not the cells of the central nervous system.

Environmental conditions clearly determine the kind of cells into which the neural crest stem cells develop. Together with colleagues from Paris, scientists from the Max Planck Institute for Brain Research in Frankfurt and the Max Planck Institute of Immunobiology and Epigenetics in Freiburg succeeded in demonstrating that, under modified conditions, these stem cells can also generate cells of the central nervous system.

They exposed stem cells from the peripheral nervous system of embryonic or postnatal mice to different culture conditions. In addition to neurons, the neural crest stem cells also developed into different types of glial cells of the central nervous system, including oligodendrocytes and astrocytes. “The culture medium reprograms the neural crest stem cells in such a way that they change their identity. This worked without genetic modification of the cells,” said Hermann Rohrer of the Max Planck Institute for Brain Research.

Factors in the culture medium clearly activated a different genetic program so that cell types developed from the stem cells, which normally would not. The scientists do not yet understand the precise factors at work here. However, there are some indications that fibroblast growth factor (FGF) is involved in this transformation.

In the brains of mice at different developmental stages, the reprogrammed stem cells mainly developed into oligodendrocytes, which form the myelin layer around the neurons of the central nervous system and are, therefore, indispensable for the transmission of electrical stimuli. Transplantation experiments carried out by the researchers on genetically modified mice that do not produce myelin and have severe neurological defects proved that the new oligodendrocytes can also assume this task.

“The reprogrammed stem cells can form cells of the central nervous system, and the new cells can permanently integrate into this system,” said Verdon Taylor of the Max Planck Institute of Immunobiology and Epigenetics.

It is not yet clear, to what extent these basic research findings will contribute to the development of cell therapy for humans. This would require that similar stem cells are present and accessible in the peripheral nervous system of humans, and that these can be propagated and reprogrammed in culture.

“At present, we only know that these stem cells in mice also have the potential to produce oligodendrocytes,” Rohrer said.

The scientists would now like to investigate in greater detail which molecular mechanisms are responsible for the reprogramming of the stem cells, whether neural crest stem cells also exist in the peripheral nervous system of adult mice and what kind of conditions are required to enable the reprogramming of these cells.

Citation: “Peripheral nervous system progenitors can be reprogrammed to produce myelinating oligodendrocytes and repair brain lesions;” Ellen Binder, Marion Rukavina, Hessameh Hassani, Marlen Weber, Hiroko Nakatani, Tobias Reiff, Carlos Parras, Verdon Taylor and Hermann Rohrer; Journal of Neuroscience, 27 April 27 2011, DOI:10.1523/JNEUROSCI.0129-11.2011

Abstract: Click here.

Contact: Hermann Rohrer, +49-699-676-9319, Hermann.Rohrer@brain.mpg.de


Scroll down to see related articles below. 
 



Related Articles :

  • Embryonic Stem Cells Restore Walking Ability In Rats With Neck Injuries - ($) (Tuesday, November 10, 2009)
    The first human embryonic stem cell treatment approved by the FDA for human testing has been shown to restore limb function in rats with neck spinal cord injuries, a finding that could expand the clinical trial to include people with cervical damage.
  • Company Reports Progress in Myelination Disorder Trial - ($) (Monday, October 11, 2010)
    Palo Alto, Calif.-based StemCells, Inc. (STEM) said two of four planned patients have been enrolled and transplanted in its ongoing Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder that afflicts male children.
  • Switzerland Okays Company’s Neural Stem Cell Trial In Spinal Cord Injury - ($) (Tuesday, December 07, 2010)
    Palo Alto, Calif.-based StemCells, Inc. (STEM) said it has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to launch a Phase I/II clinical trial in Switzerland of the company's proprietary HuCNS-SC product candidate (purified human neural stem cells) in chronic spinal cord injury.
  • Scientists Discover Precise Method Of Isolating Neural Stem Cells In Brain Tissue - ($) (Tuesday, December 07, 2010)
    Scientists have created a way to isolate neural stem cells – cells that give rise to all the cell types of the brain – from human brain tissue with unprecedented precision, an important step toward developing new treatments for conditions of the nervous system, like Parkinson's and Huntington's diseases and spinal cord injury.
  • Stanford Joins First Human Embryonic Stem Cell Trial - ($) (Tuesday, January 25, 2011)
    The Stanford School of Medicine announced its participation in the first human embryonic stem cell trial in paralyzed humans. Stanford has partnered with Santa Clara Valley Medical Center for the trial, which is run by Menlo Park-based company Geron Corp.
  • New Antibody Allows Stem Cells To Be Identified By Sugar Residues - ($) (Tuesday, May 10, 2011)
    German researchers have produced an antibody that allows them to distinguish the numerous types of stem cells in the nervous system better than before.
E-mail this stem cell article to a friend - Print this stem cell article
Articles can be e-mailed to a friend or you can get a printable version of the article.

 
Search Stem Cell Articles :
Enter key word(s)

 
 
 

 



 
 



 

Copyright © 2003 -  2014 by DataTrends Publications, Inc. All rights reserved.